References
- A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–94.
- PPCarbone, HSKaplan, KMusshoff, DWSmithers, MTubiana. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971;31:1860–1.
- JPfeiffer, GKayser, GJRidder. Sonography-assisted cutting needle biopsy in the head and neck for the diagnosis of lymphoma: can it replace lymph node extirpation? Laryngoscope 2009;119:689–95.
- YOrita, SNose, YSato, KMiki, SDomae, MHirai, et al. Cervical lymph node extirpation for the diagnosis of malignant lymphoma. Surg Today 2013;43:67–72.
- Ede Kerviler, Cde Bazelaire, NMounier, OMathieu, BBrethon, JBrière, et al. Image-guided core-needle biopsy of peripheral lymph nodes allows the diagnosis of lymphomas. Eur Radiol 2007;17:843–9.
- GMorris-Stiff, PCheang, SKey, AVerghese, TJHavard. Does the surgeon still have a role to play in the diagnosis and management of lymphomas? World J Surg Oncol 2008;6:13.
- RACowan, MJones, MHarris, WPSteward, JARadford, JWagstaff, et al. Prognostic factors in high and intermediate grade non-Hodgkin’s lymphoma. Br J Cancer 1989;59:276–82.
- RGarcía, JMHernández, MDCaballero, MGonzález, JGalende, MCdel Cañizo, et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease. Br J Cancer 1993;68:1227–31.
- AMFerraris, PGiuntini, GFGaetani. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood 1979;54:928–32.
- IBuchmann, MReinhardt, KElsner, DBunjes, CAltehoefer, JFinke, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001;91:889–99.
- AGallamini, LKostakoglu. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Blood 2012;120:4913–20.
- MWSaif, ITzannou, NMakrilia, KSyrigos. Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med 2010;83:53–65.
- SViviani, ECamerini, VBonfante, ASantoro, MBalzarotti, MFornier, et al. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin’s disease: outcome and clinical implications. Br J Cancer 1998;77:992–7.
- TTsujioka, MKishimoto, TKondo, AMatsuoka, TTasaka, TSugihara, et al. The impact of serum soluble interleukin-2 receptor levels on the diagnosis of malignant lymphoma. Kawasaki Med J 2011;37:19–27.